Advances in Cancer Immunotherapy™:
A Focus on Monoclonal Antibodies and Antibody-Drug Conjugates

This program has already taken place:

Thursday, Feb. 10, 2022
9 a.m.-1 p.m. CST
Hosted on Zoom Webinar

Join SITC and a panel of experts for an afternoon of in-depth education on recent updates in the use of monoclonal antibodies and antibody-drug conjugates clinically.

Organizers:

Christian Capitini, MD – University of Wisconsin-Madison
Hope S. Rugo, MD – University of California San Francisco Comprehensive Care Center

Program Agenda

9–9:40 a.m.	Lymphoma and Leukemia Updates Aaron Logan, MD, PhD – University of California San Francisco
9:40–10 a.m.	HER2 Targeting for Non-Breast Malignancies Updates David Ilson, MD, PhD – Memorial Sloan Kettering Cancer Center
10–10:10 a.m.	Break
10:10–10:30 a.m.	Urothelial Updates Daniel P. Petrylak, MD – Yale School of Medicine
10:30–10:55 a.m.	Pediatric Updates Patrick A. Brown, MD – Johns Hopkins University
10:55–11:05 a.m.	Break
11:05–11:45 a.m.	Breast Cancer Updates: Antibody Drug Conjugates Komal Jhaveri, MD, FACP – Memorial Sloan Kettering Cancer Center
11:45 a.m.–12:15 p.m.	ADCs and Antibodies in Practice: Emerging Toxicities and Management Strategies in Breast Cancer Aditya Bardia, MD, MPH – Massachusetts General Hospital
12:15 – 1 p.m.	Faculty Panel Aditya Bardia, MD, MPH – Massachusetts General Hospital Patrick A. Brown, MD – Johns Hopkins University Christian M. Capitini, MD – University of Wisconsin-Madison David Ilson, MD, PhD – Memorial Sloan Kettering Cancer Center Komal Jhaveri, MD, FACP – Memorial Sloan Kettering Cancer Center Aaron Logan, MD, PhD – University of California San Francisco Hope S. Rugo, MD – University of California San Francisco Comprehensive Care Center

Program Learning Objectives

Describe the mechanisms of monoclonal antibodies and antibody-drug conjugates.
Summarize recent updates in the use of monoclonal antibodies and antibody-drug conjugates clinically and toxicity management for key disease states.
Outline common toxicities with monoclonal antibodies and antibody-drug conjugates and their management.

Target Audience
The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute of Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Avoid Fraudulent ACI Registration Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org.

If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.

The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Postgraduate Institute for Medicine SITC Logo

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 1/19/2022)

The 2021-2022 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Association of Community Cancer Centers, Advances Practitioner Society for Hematology and Oncology, and Hematology/Oncology Pharmacy Association.